CelLBxHealth PLC forecasts at least £2.1 million in revenue for 2026, a 50% increase from £1.4 million in 2025, supported by a 22% expansion in its commercial pipeline. The company has restructured, cutting costs and shifting focus from research income to partnerships with pharmaceutical and diagnostic firms. Recent deals include agreements with AstraZeneca, AdventHealth, and The Royal Marsden NHS Foundation Trust, validating its new strategy. With £7.3 million cash on hand and reduced operating costs, CelLBxHealth is positioned to execute its growth plan through 2027 without immediate funding needs.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
